[go: up one dir, main page]

MX2009005787A - Metodos para tratar lupus eritematoso sistemico. - Google Patents

Metodos para tratar lupus eritematoso sistemico.

Info

Publication number
MX2009005787A
MX2009005787A MX2009005787A MX2009005787A MX2009005787A MX 2009005787 A MX2009005787 A MX 2009005787A MX 2009005787 A MX2009005787 A MX 2009005787A MX 2009005787 A MX2009005787 A MX 2009005787A MX 2009005787 A MX2009005787 A MX 2009005787A
Authority
MX
Mexico
Prior art keywords
methods
lupus erythematosus
systemic lupus
treating systemic
treating
Prior art date
Application number
MX2009005787A
Other languages
English (en)
Inventor
Barbara White
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2009005787A publication Critical patent/MX2009005787A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)

Abstract

La presente invención se relaciona con un método de tratamiento de SLE en un sujeto humano que comprende la administración de un anticuerpo anti-interferón ?.
MX2009005787A 2006-12-06 2007-12-06 Metodos para tratar lupus eritematoso sistemico. MX2009005787A (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US87300806P 2006-12-06 2006-12-06
US90776707P 2007-04-16 2007-04-16
US90776207P 2007-04-16 2007-04-16
US92421907P 2007-05-03 2007-05-03
US92422007P 2007-05-03 2007-05-03
US92458407P 2007-05-21 2007-05-21
US96018707P 2007-09-19 2007-09-19
US99617407P 2007-11-05 2007-11-05
US99617607P 2007-11-05 2007-11-05
US99621907P 2007-11-06 2007-11-06
US99682007P 2007-12-06 2007-12-06
PCT/US2007/024941 WO2008070135A2 (en) 2006-12-06 2007-12-06 Methods of treating systemic lupus erythematosus
PCT/US2007/024947 WO2008070137A2 (en) 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers

Publications (1)

Publication Number Publication Date
MX2009005787A true MX2009005787A (es) 2009-06-08

Family

ID=39492862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005787A MX2009005787A (es) 2006-12-06 2007-12-06 Metodos para tratar lupus eritematoso sistemico.

Country Status (10)

Country Link
US (5) US20100143372A1 (es)
EP (3) EP2077858A4 (es)
JP (4) JP2010512315A (es)
KR (2) KR101532797B1 (es)
AU (2) AU2007327993B2 (es)
BR (2) BRPI0720035A2 (es)
CA (2) CA2670897A1 (es)
MX (1) MX2009005787A (es)
RU (2) RU2527068C2 (es)
WO (2) WO2008070135A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101532797B1 (ko) * 2006-12-06 2015-07-01 메디뮨 엘엘씨 인터페론 알파 유도성 약력학적 마커
AU2008247398B2 (en) * 2007-05-03 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
ES2542836T3 (es) * 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
MX2010004814A (es) 2007-11-05 2010-08-10 Medimmune Llc Metodos para tratar esclerodermia.
WO2009100342A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CA2796666C (en) 2010-04-21 2020-04-14 MeMed Diagnostics, Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
JP2014501263A (ja) * 2010-12-22 2014-01-20 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ Ｈｉｖプロテアーゼ阻害剤を用いて全身性エリテマトーデスを治療する方法
AU2013204880B2 (en) * 2011-04-26 2016-11-24 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2012149228A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
GB201115665D0 (en) * 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CA3133249C (en) 2012-02-09 2023-07-25 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP2850437A4 (en) 2012-05-17 2016-01-13 Univ Johns Hopkins METHOD FOR IDENTIFYING PATTERNS OF IFN-INDUCED EXPRESSION AND USE FOR DIAGNOSIS, MONITORING AND THERAPY PURPOSES
WO2013188494A1 (en) * 2012-06-13 2013-12-19 Medimmune, Llc Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
US20140039907A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for collecting patient data with a portable electronic device
US20140156297A1 (en) * 2012-08-03 2014-06-05 Axelacare Holdings, Inc. Computer program, method, and system for pharmacist-assisted treatment of patients
US20140275257A1 (en) * 2013-03-14 2014-09-18 Foundation for the State University of New York N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
KR20170041907A (ko) 2014-08-14 2017-04-17 메메드 다이어그노스틱스 리미티드 매니폴드 및 초평면을 이용한 생물학적 데이터의 컴퓨터 분석법
CN105420347A (zh) * 2014-08-21 2016-03-23 南京大学医学院附属鼓楼医院 一种用于系统性红斑狼疮的基因诊断试剂盒
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
CN109661578B (zh) 2016-07-10 2022-05-10 米密德诊断学有限公司 用于区分细菌和病毒感染的蛋白质特征
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
CN110073220A (zh) 2016-09-29 2019-07-30 米密德诊断学有限公司 风险评估和疾病分类的方法
US20200008916A1 (en) * 2016-12-16 2020-01-09 The Penn State Research Foundation Methods for improved reproductive management of ruminant ungulates
WO2018136625A2 (en) * 2017-01-20 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2019020593A1 (en) * 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3873523A4 (en) * 2018-10-26 2022-08-10 Janssen Biotech, Inc. TYPE I INTERFERON SIGNATURES AND METHODS OF USE
EP3891123A4 (en) 2018-12-03 2022-12-14 Board of Regents, The University of Texas System OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN THE TREATMENT OF CANCER
CN113508138B (zh) 2019-02-15 2024-08-09 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
KR102429261B1 (ko) 2020-08-25 2022-08-03 충북대학교 산학협력단 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커
TW202228705A (zh) * 2020-10-02 2022-08-01 美商西建公司 治療全身性紅斑性狼瘡之方法及生物標記作為對療法之臨床敏感性之預測子之用途
WO2022223714A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection
WO2022266414A1 (en) 2021-06-18 2022-12-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
FR3138815A1 (fr) * 2022-08-12 2024-02-16 bioMérieux Détermination de la nature virale ou bactérienne d’une infection
CN117305441B (zh) * 2023-10-13 2025-04-08 福建农林大学 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
FR2692168B1 (fr) 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US6905587B2 (en) * 1996-03-22 2005-06-14 Ronald Redline Method for enhancing the solderability of a surface
AU749032B2 (en) 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
AU2002365514A1 (en) * 2001-11-30 2003-06-10 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
DK1569696T3 (da) * 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
AU2004271200A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US7741449B2 (en) * 2003-12-10 2010-06-22 Medarex, Inc. Anti-interferon alpha antibodies
DK2662390T3 (da) * 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
WO2006023966A2 (en) * 2004-08-24 2006-03-02 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Assessment of cardiovascular risk
US7571055B2 (en) * 2004-10-13 2009-08-04 Regents Of The University Of Minnesota Systemic lupus erythematosus
RU2431638C2 (ru) * 2005-02-10 2011-10-20 Бэйлор Рисерч Инститьют Моноклональные антитела против интерферона-альфа и способы применения
US20070117105A1 (en) * 2005-05-12 2007-05-24 Crow Mary K Interferon assay
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
AU2006278561C1 (en) * 2005-08-05 2013-05-02 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
EP2057190A4 (en) * 2006-08-09 2010-07-28 Baylor Res Inst MONOCLONAL ANTI-INTERFERON ALPHA ANTIBODIES AND USE METHOD THEREFOR
KR101532797B1 (ko) * 2006-12-06 2015-07-01 메디뮨 엘엘씨 인터페론 알파 유도성 약력학적 마커
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1

Also Published As

Publication number Publication date
BRPI0720035A2 (pt) 2019-05-07
EP2077858A4 (en) 2011-07-20
KR20090088931A (ko) 2009-08-20
WO2008070137A3 (en) 2008-11-20
JP2010512313A (ja) 2010-04-22
WO2008070135A2 (en) 2008-06-12
RU2527068C2 (ru) 2014-08-27
JP2014040430A (ja) 2014-03-06
EP2073844A2 (en) 2009-07-01
EP2712930A2 (en) 2014-04-02
AU2007327995A1 (en) 2008-06-12
AU2007327993A1 (en) 2008-06-12
CA2670897A1 (en) 2008-06-12
AU2007327995B2 (en) 2013-10-10
WO2008070135A3 (en) 2008-11-27
RU2009125616A (ru) 2011-07-27
KR101532797B1 (ko) 2015-07-01
RU2014127178A (ru) 2016-01-27
US20100143373A1 (en) 2010-06-10
CA2670594A1 (en) 2008-06-12
AU2007327993B2 (en) 2013-06-20
EP2712930A3 (en) 2014-04-23
US20150147336A1 (en) 2015-05-28
JP2010512315A (ja) 2010-04-22
US20170121771A1 (en) 2017-05-04
US20100143372A1 (en) 2010-06-10
KR20090088932A (ko) 2009-08-20
JP2014014370A (ja) 2014-01-30
EP2077858A2 (en) 2009-07-15
WO2008070135A8 (en) 2009-12-17
US20150044222A1 (en) 2015-02-12
BRPI0719912A2 (pt) 2014-03-04
WO2008070137A2 (en) 2008-06-12
EP2073844A4 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
MX2009005787A (es) Metodos para tratar lupus eritematoso sistemico.
IL195382A0 (en) Il-17 and il-23 antagonists and methods of using the same
ZA201102004B (en) Antibodies against human il 17 and uses thereof
PL4032979T3 (pl) Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania
IL198020A0 (en) Anti-cd20 antibodies and methods of use
IL225482A (en) Air lane assembly and methods for using an air lane assembly
EP1945322A4 (en) SYSTEMS AND METHODS FOR MANAGING AN EXERCISE PROGRAM
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
PL2358756T5 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
IL193846A0 (en) Methods for regulating inflammatory mediators and peptides useful therein
ZA200807278B (en) Antibodies against human IL-22 and uses therefor
IL193604A0 (en) Methods of using antibodies against human il-22
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
SI1973950T1 (sl) Anti-EphB4 protitelesa in postopki njihove uporabe
GB2476756B (en) Varible turbo supercharger and method of driving the same
EP2034959A4 (en) OPTIMIZED FLUORO CARBON EMULSIONS FOR BLOOD SUBSTITUTES AND OTHER THERAPEUTIC USES
IT1397996B1 (it) Endoreattore e metodo di controllo della combustione nell'endoreattore stesso.
GB0615635D0 (en) Immunogenic proteins and uses thereof
GB0427696D0 (en) Method of authenticating an executable application
EP2164513A4 (en) PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND METHOD FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
ZA200900543B (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
EP2204271A4 (en) PROCESS FOR INJECTING POLYVINYL ALCOHOL (PVA) PARTS AND PARTS SO OBTAINED
GB2435914B (en) Anchor and method of operating the same
TWI370374B (en) Feeling search engine and method of the same
IL185318A0 (en) Engine and methods thereof

Legal Events

Date Code Title Description
FG Grant or registration